Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
↘️ Amgen (AMGN): Shares of the biotechnology company, a major contributor to the Dow, shed more than 5% premarket after the Swiss drugmaker Novartis (CH:NOVN) said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial.
Stocks were on track to open lower on Tuesday as investors fretted about the disruption of oil shipments through the Strait of Hormuz. Dow Jones Industrial Average futures slumped 479 points, or 0.9%. S&P 500 futures dropped 0.4%.
U.S. markets wobbled as higher oil prices dragged sentiment before investors return from the Labor Day weekend.
Novartis lowered the target biomarker without reducing events; olpasiran must prove the mechanism can still deliver.
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Trump's latest MFN drug-pricing deals create a mixed outlook for the broader healthcare sector ETFs.
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.
Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...
Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...
One regulatory setback is starting to look much broader
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Amgen and AstraZeneca (LSE:AZN) reported positive top line Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with clinically meaningful improvements through week 52. That kind of readout often prompts investors to revisit AstraZeneca stock. Even with a steady stream of late stage trial updates around TEZSPIRE, Tagrisso combinations and Enhertu, AstraZeneca’s share price has drifted, with a year to date share price return down 10.87% at £121.14. The 5 year total shareholder return of...
Tezspire met both primary endpoints in an esophagitis trial, but AstraZeneca shares slipped roughly 0.6% Thursday.
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
